Drug Type Small molecule drug |
Synonyms Ceforanide (USP/INN), BL-S786, NSC-760049 + [2] |
Target |
Mechanism PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date US (24 May 1984), |
Regulation- |
Molecular FormulaC20H21N7O6S2 |
InChIKeySLAYUXIURFNXPG-CRAIPNDOSA-N |
CAS Registry60925-61-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00259 | Ceforanide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Bacterial Infections | US | 24 May 1984 | |
Surgical Wound Infection | US | 24 May 1984 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bone and joint infections | Phase 1 | CN | 27 Aug 2018 | |
Bone and joint infections | Phase 1 | CN | 27 Aug 2018 | |
Endocarditis | Phase 1 | CN | 27 Aug 2018 | |
Endocarditis | Phase 1 | CN | 27 Aug 2018 | |
Infections of musculoskeletal system | Phase 1 | CN | 27 Aug 2018 | |
Infections of musculoskeletal system | Phase 1 | CN | 27 Aug 2018 | |
Peritonitis | Phase 1 | CN | 27 Aug 2018 | |
Peritonitis | Phase 1 | CN | 27 Aug 2018 | |
Pyelonephritis | Phase 1 | CN | 27 Aug 2018 | |
Pyelonephritis | Phase 1 | CN | 27 Aug 2018 |